Latest Steatohepatitis Stories
DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease
ReportsnReports.com offers "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" 2014 market research report in
Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals
In-demand research report “OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017” elaborated by GlobalData has been recently published by Market
New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis.
MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis
RnRMarketResearch.com adds Latest Report on “OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017” to its store.
A groundbreaking study of nearly 2,300 extremely obese diabetes patients, led by the Translational Genomics Research Institute (TGen), has identified genes associated with unhealthy liver function.
A new, non-invasive imaging technique, magnetic resonance elastography (MRE), can now help physicians accurately detect fibrosis (scarring) in children with chronic liver disease – a growing problem due in part to increasing obesity rates.